Randomized, Controlled Biomarker Study Evaluating the Anti-Angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Sunitinib (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- 16 Nov 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 17 Aug 2010 Planned end date changed from Jun 2010 to Jul 2011 as reported by ClinicalTrials.gov.
- 04 Jun 2010 Interim results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.